Skip to content
Clinical ResearchResearch compound

S4 (Andarine, GTx‑007)

Experimental SARM that can cause yellow-tinted vision and night blindness; never approved as a medicine, with few studies in humans.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

S4 (Andarine, GTx-007) vial

Related comparisons

LGD-4033 vs S23 vs S4

DETAILED OVERVIEW

What is S4 (Andarine, GTx-007)?

S4 (Andarine, GTx-007) is an experimental compound, one of the non-steroidal substances called SARMs, which trigger male-hormone-like effects in muscle and bone. GTx Inc. studied it for an enlarged prostate and for cachexia (severe wasting with weight loss) but moved on to another compound, and it was never approved as a medicine. Only a few small studies have been done in humans. Bodybuilders mention it as a fat-loss aid, without proof.

Its characteristic side effect is a vision disturbance: according to user reports, yellow-tinted vision is very common, and at higher doses night blindness can also appear. Both go away within weeks of stopping. It lowers the body’s own testosterone production, may reduce HDL cholesterol, and liver damage can occur. In women it can cause masculinization that may be partly permanent. It must not be used in pregnancy or breastfeeding, because it can masculinize the fetus. It is banned in competitive sport year-round.

Mechanism

Androgen receptor modulator; also binds light-sensing proteins in the eye

Anabolic activity (Gao 2005)

In rat bioassay anabolic activity ~60-70% Test-level (in vivo)

Half-life

About 4 hours (oral; short)

Onset

1-2 weeks

Legal status

Never an Rx (GTx deprioritized after Phase II in 2010). UGL 'research chemical'. WADA-banned S1.2.

Data console

Lab data

Androgenic:Anabolic~65:20 (muscle:prostate selectivity, Gao 2005 PMID 16270235 rat bioassay)
AR bindingNon-steroidal SARM, AR binding ~70% testosterone-level in…
Active half-life~4 h
Detection windowUrinary: 1-2 weeks S4 metabolites by LC-MS/MS (WADA-accredited). Shorter than RAD/LGD due to faster clearance.
AromatizationNO – non-steroidal, NOT a CYP19 substrate.
HepatotoxicityModerate – short half-life (~4 h) makes reactive-metabolite clearance faster than RAD/LGD. NOT zero – Solomon 2019 SARM-DILI review documented 1 S4-associated hepatocellular injury case.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Dose-dependent yellow tint vision: blue-light perception dulls and the color palette shifts toward yellow-green. Reported by roughly 30% of users at 50+ mg/day (retinal opsin binding, Marhefka 2004).
  • Night blindness at high doses (>75 mg/day) in roughly 10-20% of users, due to rod-opsin involvement and reduced low-light vision. Reversible within 4-6 weeks after discontinuation.
  • HPTA suppression (lowered endogenous testosterone, LH/FSH): milder than with LGD-4033 or RAD-140 because of the short (~4 h) half-life, but not zero, PCT is usually needed.
  • Adverse lipid shift: drop in HDL cholesterol, typical of the SARM class. Lipid disturbance is moderate on S4 but should be monitored.
  • Hepatotoxicity (liver injury): moderate, milder than with RAD/LGD due to faster reactive-metabolite clearance from the short half-life, but not zero, SARM-associated drug-induced liver injury (DILI) is documented with S4 too.
  • Virilization in women at higher doses: voice deepening, increased hair growth, acne, menstrual disruption. Some androgenic effects (e.g. voice changes) can be permanent.
  • Compliance and daily-fluctuation risk: the short (~4 h) half-life requires 2-3 doses per day, missed doses cause unstable effect and unpredictable onset of side effects.

Contraindications · 7

  • Pre-existing eye disease or visual disorder (glaucoma, retinopathy, retinal/opsin involvement): absolute contraindication because of S4's retinal opsin-binding visual side effect.
  • Occupations where night vision is critical (driver, pilot, machine operator): the risk of night blindness and yellow vision creates an accident hazard.
  • Pregnancy and breastfeeding: androgenic activity can cause fetal virilization, absolutely to be avoided.
  • Planned fatherhood or existing subfertility: HPTA suppression transiently impairs spermatogenesis, recovery can take 2-3 months.
  • Pre-existing liver disease or elevated liver enzymes: increases the risk of SARM-associated hepatotoxicity.
  • Competitive sport under WADA rules: S4 is banned year-round (S1.2), detectable in urine for 1-2 weeks, the faster clearance offers no hiding place.
  • Dyslipidemia or cardiovascular risk: the HDL drop worsens the lipid profile, increased monitoring or avoidance is warranted.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about S4 (Andarine, GTx‑007)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.